Chr. Augustinus Fabrikker invests EUR 48 million to acquire an ownership stake of just over one third of the shares
Abacus Medicine welcomes investment company Chr. Augustinus Fabrikker as strategic shareholder
Abacus Medicine decided today to postpone the planned Initial Public Offering (IPO) due to the currently unfavourable market conditions.
Abacus Medicine adopted a new CSR Policy for 2018 and publishes a CSR Report for the first time this year.
Our best year ever. Revenue rose by 31% and Adjusted EBITDA by 39%.
After the first 6 days, we are very satisfied with our production setup and IT infrastructure.
Abacus Medicine extends cooperation with pharmaceutical wholesaler Pluripharm Group
New site will offer daily flexibility and provide a contingency solution
Simon Estcourt to head global activities for Aposave, the Abacus Medicine group’s pharmaceutical services company
In October 2018, Abacus Medicine announced and later postponed an Initial Public Offering (IPO) on the Frankfurt Stock Exchange.